Disease-A-Month
Volume 53, Issue 6 , Pages 313-335 , June 2007

Substance-Related Disorders in Adults

References 

  1. In: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., revised. Washington, D.C: American Psychiatric Press; 1994;
  2. Petty TL. The early diagnosis of lung cancer. Disease-a-Month. 2001;47(6):204–258
  3. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606–2610
  4. Olmedo R, Hoffman RS. Withdrawal syndromes. Emerg Med North Am. 2000;18(2):273–288
  5. Olmedo RE, Nelson L, Howland M, et al. Propofol safely controls delirium tremens. J Toxicol Clin Toxicol. 2000;38(5):537
  6. Foy A. The pathophysiology, diagnosis and management of alcohol withdrawal. J Toxicol Clin Toxicol. 2000;38(2):189–190
  7. Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med. 2006;119(3):276
  8. Leggio L, Abenavoli L, Caputo F, et al. Baclofen use in the treatment of alcohol delirium tremens. Arch Intern Med. 2005;165(5):586
  9. Meythaler JM, Roper JF, Brunner RC. Cyproheptadine for intrathecal baclofen withdrawal. Arch Phys Med Rehabil. 2003;84(5):638–642
  10. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated feature. Psychopharmacol. 2004;176(1):1–29
  11. O’Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998;279(3):229–234
  12. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med. 2001;37(2):147–153
  13. Craig K, Gomez HF, McManus JL, et al. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med. 2000;18(1):65–70
  14. Mullins ME, Fitzmaurice SC. Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. J Emerg Med. 2001;20:418–419
  15. Sivilotti ML, Burns MJ, Aaron CK. Pentobarbital for control of acute delirium due to gamma-butyrolactone withdrawal. Ann Emerg Med. 2000;35(5):S52–S53
  16. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am. 2000;18(2):317–325
  17. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psych. 1997;58(7):291–297
  18. Khazaal Y. Mania after venlafaxine withdrawal in a patient with generalized anxiety disorder. Ann Pharmacother. 2007;41:359–360
  19. Schechter JO. Treatment of disequilibrium and nausea in the SSRI discontinuation syndrome. J Clin Psychiatry. 1998;59(8):431–432
  20. Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Psychopharmacology (Berl). 2004;176(1):1–29
  21. In:  Gelenberg AL,  Bassuk EL editor. The Practitioners Guide to Psychoactive Drugs. 4th ed.. New York, NY: Plenum Medical Book Co; 1997;p. 291–363

 Adapted with permission from Drug Information Handbook for Psychiatry, 6th edition, Fuller MA and Sajatovic M, eds, Lexi-Comp Inc: Hudson, Ohio, 2007. Available at www.lexi.com. The following portions of text are original work by author Leikin, J: Baclofen, SSRIs and Caffeine.

PII: S0011-5029(07)00022-3

doi: 10.1016/j.disamonth.2007.04.001

Disease-A-Month
Volume 53, Issue 6 , Pages 313-335 , June 2007

Article Tools